The Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetes
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This study builds on data that high-density lipoprotein (HDL) has a number of potentially
beneficial effects including directly modulating glucose metabolism through multiple
mechanisms. The primary objective of this study is to determine the effects of RVX000222 on
postprandial plasma glucose in male individuals with impaired fasting glucose (IFG) or
impaired glucose tolerance (IGT), during a frequently sampled oral glucose tolerance test
(OGTT).
Phase:
Phase 2
Details
Lead Sponsor:
Resverlogix Corp
Collaborators:
Baker Heart and Diabetes Institute Baker IDI Heart and Diabetes Institute Nucleus Network Ltd